Monrovia, California (PressExposure) November 22, 2011 -- Francisco Leon, Vice President of Immunology Translational Medicine at Janssen, a division of Johnson & Johnson, will speak in and chair the session: Translational Medicine in Immunology through Four Success Stories at the 10th Cytokines and Inflammation Conference to be held in San Diego, CA on January 30-31, 2012 by GTC.
Translational research can be defined as the bi-directional process of applying clinical knowledge to basic research and scientific knowledge to clinical development. The benefits of translational research are shorter clinical development timelines and reduced risk by enabling earlier and more robust science-based decision making.
The Translational Medicine session will review 4 success stories as examples of translational research put into practice. The talks will cover autoimmunity, allergy and transplantation and will illustrate the journey of several breakthrough medicines from the lab to the patients who need them. Below is an overview of the 4 success stories:
"Belatacept: Fine Tuning Co-stimulation Blockade - From Bench to Bedside" by Robert Townsend, Director of Clinical Biomarkers at Bristol-Myers Squibbf
"Targeting the Type 1 Interferon Pathway for the Treatment of Lupus" by Roland Kolbeck, Director of Respiratory, Inflammation and Autoimmunity at MedImmune
"IL-13 in Inflammatory and Allergic Diseases" by Peter J. Mannon, Professor of Medicine, Division of Gastroenterology and Hepatology at the University of Alabama
"Therapeutic Targeting of the IL-12/23 Pathways with Ustekinumab" by Kim Campbell, Director of Immunology Product Support at Janssen
Francisco Leon, Vice President of Immunology Translational Medicine at Janssen (Johnson and Johnson) is a clinical immunologist trained in Spain and at the NIH. His basic research focus has been mucosal immunology while his biotech and pharmaceutical experience span most areas of early development in Immunology. Francisco has occupied positions of increased responsibility in Bristol-Myers Squibb, MedImmune and Alba Therapeutics before joining Centocor, now Janssen, in 2010.
The10th Cytokines and Inflammation Conference will bring together a 50-50 mix of academic and industry authoritative experts from leading affiliations (such as Biogen Idec, Merck, ChemoCentryx, FDA, Abbott, Janssen, BMS, MedImmune, Centocor, NIH, Scripps, UCSD, Stanford, UCLA, Sanford-Burnham, LIAI, etc.) to cover many current and relevant aspects of basic, translational or full development cytokine biology and its applicability to human health.
This conference is also part of the Novel Immunotherapeutics Summit, which consists of this track and three other tracks:
1) 4th Immunotherapeutics and Immunomonitoring
2) Immunotherapeutics Partnering and Dealmaking
3) Allergy Drug Discovery and Development
For more information, please visit http://www.gtcbio.com